TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00856024

Intervention type: BIOLOGICAL
Intervention: Peginterferon alfa-2b
Description: PegIntron 80 μg, PegIntron 100 μg, or PegIntron 120 μg. The duration of the complete treatment and the doses of pegylated interferon alfa 2b should have been prescribed according to local guidelines, and according to the investigating physician's orientation.

Intervention type: BIOLOGICAL
Intervention: Peginterferon alfa-2b
Description: PegIntron 80 μg, PegIntron 100 μg, or PegIntron 120 μg. The duration of the complete treatment and the doses of pegylated interferon alfa 2b should have been prescribed according to local guidelines, and according to the investigating physician's orientation.

Intervention type: DRUG
Intervention: Ribavirin
Description: Ribavirin 250 mg. The duration of the complete treatment and the doses of ribavirin should have been prescribed according to local guidelines, and according to the investigating physician's orientation.

Intervention type: DRUG
Intervention: Ribavirin
Description: Ribavirin 250 mg. The duration of the complete treatment and the doses of ribavirin should have been prescribed according to local guidelines, and according to the investigating physician's orientation.

Intervention type: DRUG
Intervention: Ribavirin
Description: Ribavirin 250 mg. The duration of the complete treatment and the doses of ribavirin should have been prescribed according to local guidelines, and according to the investigating physician's orientation.
Study: NCT00560261

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NO-CO inhalation and expiration
Description: NO-CO inhalation and expiration
Study: NCT00832286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: Licensed medication, dose: 500 mg every 12 hours for 3 days.
Study: NCT04172727

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hcl 0.25% Inj
Description: ultrasound-guided bilateral TFP block with 20 mL of 0.25% bupivacaine
Study: NCT00560261

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NO-CO inhalation and expiration
Description: NO-CO inhalation and expiration
Study: NCT04172727

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline 0.9%
Description: ultrasound-guided bilateral TFP block with 20 mL of saline 0.9%
Study: NCT01338701

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Acupuncture (TCA)
Description: An acupuncturist will examine and evaluate subjects before inserting thin, sterile stainless steel needles at specific points on their body. Patients will receive 10 treatments over a 6 week period.
Study: NCT04080765

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV-ASSIST
Description: HIV-ASSIST is an online interactive patient-based tool that allows for individualized HIV treatment recommendations through the synthesis of patient-specific factors with existing guidelines and evidence.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DHHS guidelines
Description: This is the Department of Health and Human Services HIV/AIDS Treatment Guidelines.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DHHS guidelines
Description: This is the Department of Health and Human Services HIV/AIDS Treatment Guidelines.
Study: NCT04409782

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic portal education
Description: Participants will receive education via an electronic portal covering the key messages pertaining to cancer research studies and clinical trials. Data will be collected via pre- and post-tests. The post-test includes questions to pre-screen participants for eligibility into cancer research studies and clinical trials; as appropriate, study participants will be referred to those study/trial/clinical teams for follow-up.
Study: NCT01338701

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Auricular (Ear) Acupuncture
Description: An acupuncturist will insert sterile stainless steel needles and an ASP ear needle into various points in subject's outer ear. The ASP is a shorter needle that will stay in the participant's ear for a few days. Patients will receive 10 treatments over a 6 week period.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Subjects do not receive acupuncture during the 6 week study time period. Instead, they continue to receive medical care for headaches and other symptoms. They can elect to receive up to 10 ear acupuncture treatments between the 6- and 12-week assessments.
Study: NCT04409782

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online educational video
Description: Participants will receive online education via a video and written web content. Key messages will include information pertaining to cancer research studies and clinical trials. Data will be collected via pre- and post-tests. The post-test includes questions to pre-screen participants for eligibility into cancer research studies and clinical trials; as appropriate, study participants will be referred to those study/trial/clinical teams for follow-up.
Study: NCT03915041

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR + active brain stimulation
Description: Active Brain stimulation (tDCS) is applied during exposition to virtual reality (20 minutes)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: VR +sham brain stimulation
Description: Sham Brain stimulation (tDCS) is applied during exposition to virtual reality (20 minutes)
Study: NCT01579396

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: septeX
Description: 12 h septeX CVVH treatment after cardiac surgery

Intervention type: OTHER
Group type: OTHER
Intervention: standard therapy
Description: standard therapy either pharmacological and /or continuous renal replacement therapy (CRRT)
Study: NCT00820924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAPATINIB
Description: LAPATINIB 1500MG ORAL DOSE DAILY
Study: NCT00972491

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Insertion of Laryngeal Mask Airway
Description: The LMA will be inserted at 0 sec, 60 sec. and 90 sec. after induction of general anesthesia
Study: NCT02922452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986141
Description: Single dose BMS-986141 and Multiple doses of Dilitazem

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dilitazem
Description: Single dose BMS-986141 and Multiple doses of Dilitazem
Study: NCT01872871

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: paracetamol with local anesthetic eye drop versus placebo with local anesthetic eye drops

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical anaesthetic drop with placebo
Study: NCT05488899

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Half iodine Spectral CT
Description: Patients receive half dosage of iodine contrast agent, and Spectral CT acquisition with Virtual Monoenergetic Images at 40 and 50 keV.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard iodine conventional CT
Description: Patients receive standard dosage of iodine contrast agent, and conventional 120 kv Polychromatic CT acquisition.
Study: NCT01843439

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Magnesium

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education for asthma action plan

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: hot-lines for acute exacerbation of asthma

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inhaler technique training
Study: NCT02007512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: 160 mg/day administered as four 40mg soft gelatin capsules by mouth once daily with or without food.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exemestane
Description: 25mg (overencapsulated to match 50mg dose during the blinded portion of the study and one 25mg tablet after unblinding) by mouth once daily after food.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for enzalutamide)
Description: Sugar pill manufactured to mimic enzalutamide administered as four soft gelatin capsules by mouth once daily with or without food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: 50mg (two 25mg tablets overencapsulated as a single capsule during the blinded portion of the study and two 25mg tablets after unblinding) by mouth once daily after food.
Study: NCT00192075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 900 mg/m2 IV over 90 minutes after Folinic Acid weekly for 6 weeks every 8 weeks until progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avastin
Description: 5 milligrams per kilogram (mg/kg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: avastin
Description: 5 milligrams per kilogram (mg/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5FU/folinic acid
Description: Folinic Acid: 100 milligrams per square meter (mg/m2) intravenous (IV) over 60 minutes (A+FFG).~Folinic Acid: 200 mg/m2 as a 2-hr infusion on Days 1 and 2 of a 14-day cycle (A+FOLFOX 4).~5-Fluorouracil: 450 mg/m2 as an IV bolus in middle of Folinic Acid (A+FFG). 5-Fluorouracil: 400 mg/m2 bolus plus a 600 mg/m2 22-hour infusion on Days 1 and 2 of a 14-day cycle (A+FOLFOX 4).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5FU/folinic acid
Description: Folinic Acid: 100 milligrams per square meter (mg/m2) intravenous (IV) over 60 minutes (A+FFG).~Folinic Acid: 200 mg/m2 as a 2-hr infusion on Days 1 and 2 of a 14-day cycle (A+FOLFOX 4).~5-Fluorouracil: 450 mg/m2 as an IV bolus in middle of Folinic Acid (A+FFG). 5-Fluorouracil: 400 mg/m2 bolus plus a 600 mg/m2 22-hour infusion on Days 1 and 2 of a 14-day cycle (A+FOLFOX 4).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin
Description: 85 mg/m2 as a 2-hour infusion on Day 1 of a 14 day cycle.
Study: NCT02379442

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC
Description: MSC are an adherent, fibroblast-like cell population found in the bone marrow. Allogeneic MSC for treatment can be grown from bone marrow aspirates or biopsies of normal donors.
Study: NCT01446562

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Y90 Ibritumomab Tiuxetan RIT
Description: 40 mCi/kg
Study: NCT04709965

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Face2Gene
Description: This study investigates whether a new diagnostic intervention (Face2Gene facial recognition software) is better than using standard approach to diagnosis.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Face2Gene
Description: This study investigates whether a new diagnostic intervention (Face2Gene facial recognition software) is better than using standard approach to diagnosis.
Study: NCT03773393

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CK0801
Description: CK0801 (a Cord blood-derived T-regulatory cell product)
Study: NCT00633009

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Leishmania tropica Skin Test Antigen (LtSTA)
Description: Administer 15 ug, 30 ug or 50 ug of LtSTA into DTH positive volunteers. Repeat drug administration 30 days after initial injection and 60 days after initial injection. Read and interpret reaction 48 hours after each injection. Observe subjects for conversion or adverse reaction.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Leishmania tropica Skin Test Antigen (LtSTA)
Description: Administer 15 ug, 30 ug or 50 ug of LtSTA into DTH positive volunteers. Repeat drug administration 30 days after initial injection and 60 days after initial injection. Read and interpret reaction 48 hours after each injection. Observe subjects for conversion or adverse reaction.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Leishmania tropica Skin Test Antigen (LtSTA)
Description: Administer 15 ug, 30 ug or 50 ug of LtSTA into DTH positive volunteers. Repeat drug administration 30 days after initial injection and 60 days after initial injection. Read and interpret reaction 48 hours after each injection. Observe subjects for conversion or adverse reaction.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Leishmania tropica Skin Test Antigen Placebo (Placebo)
Description: Administer Placebo concurrently with 15 ug, 30 ug and 50 ug doses of LtSTA. Read and interpret the reaction 48 hours after injection. Observe subjects for reaction to Placebo

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Leishmania tropica Skin Test Antigen Placebo (Placebo)
Description: Administer Placebo concurrently with 15 ug, 30 ug and 50 ug doses of LtSTA. Read and interpret the reaction 48 hours after injection. Observe subjects for reaction to Placebo

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Leishmania tropica Skin Test Antigen Placebo (Placebo)
Description: Administer Placebo concurrently with 15 ug, 30 ug and 50 ug doses of LtSTA. Read and interpret the reaction 48 hours after injection. Observe subjects for reaction to Placebo
Study: NCT02902107

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CivaSheet

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical resection
Study: NCT01813981

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low roast coffee
Description: Instant coffee
Study: NCT03584035

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sensory motor integration exercises
Description: Sensorimotor integration exercises will be given in study group. The exercises will be performed in standing, sitting and walking. Exercises will be progressively increased from eye open to closed , floor to mat and head turns to right \& left under the supervision of physiotherapist. Sensorimotor integration exercises will take 45 minutes in each session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: conventional physiotherapy
Description: Conventional physiotherapy will take 30 minutes in each session, taking three sessions per weeks for six weeks. The exercises include simple lower extremity exercise and ambulatory training such as sit to stand, stepping, lateral and backward walking, and tandom walking etc.
Study: NCT01813981

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: High roast coffee
Description: Instant coffee

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control (Caffeine dissolved in water)
Description: Caffeine dissolved in water
Study: NCT03427658

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sweet food consumption
Description: Comparison of the impacts of sweet and non-sweet food consumption
Study: NCT04036786

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: study group
Description: We prepared a preeclampsia education booklet in accordance with the literature,The content of the booklet was guided by the opinion of experts. It was written in easily understandable language and contained attractive and colorful illustrations. This booklet contents were definition and risk factors for the development of preeclampsia, maternal and fetal damages, recommendations for preventing its development (diet, rest, study, exercise, coping with stress techniques), follow-up of symptoms at home (blood pressure, weight and edema follow-up, counting fetal movements), danger signs, drug use, follow up in hospital, risk of developing in subsequent pregnancies, and its results. Pregnant women in the study group were given education and counseling at four times in addition to standard care, using the preeclampsia education booklet, in a special place. The participants' questions were answered, and each received a copy of the booklet.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: standard care
Description: standard pregnancy follow up
Study: NCT02297438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
Study: NCT03427658

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sweet food consumption
Description: Comparison of the impacts of sweet and non-sweet food consumption
Study: NCT01857258

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Green Tea Concentrate
Description: Green tea concentrate is being examined as a dietary supplement that can regulate postprandial excursions in blood glucose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Green Tea Concentrate
Description: Green tea concentrate is being examined as a dietary supplement that can regulate postprandial excursions in blood glucose
Study: NCT04613180

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast Sodium
Description: Montelukast is used to prevent wheezing, difficulty breathing, chest tightness, and coughing caused by asthma in adults and children 12 months of age and older. Montelukast is also used to prevent bronchospasm (breathing difficulties) during exercise in adults and children 6 years of age and older.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo containing no active substance
Study: NCT00348205

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Technolas 217z Zyoptix Laser
Description: Technolas 217z Zyoptix System with Treatment Planner Customized Treatment Calculation Software for the wavefront-guided LASIK treatment of hyperopia and hyperoptic astigmatism.
Study: NCT02297438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole, 2.5mg, orally once daily (continuously)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Letrozole, 2.5mg, orally once daily (continuously)
Study: NCT03922984

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI with Arterial Spin Labeling (ASL)
Description: Week 0 (Before initiation of chemoradiation): MRI with ASL will be performed along with patient's standard of care imaging session Week 3: contrast-enhanced research MRI with ASL Week 6: contrast-enhanced research MRI with ASL Week 10: MRI with ASL will be performed along with patient's standard of care imaging session Week 18: MRI with ASL will be performed along with patient's standard of care imaging session Week 26: MRI with ASL will be performed along with patient's standard of care imaging session Week 34: MRI with ASL will be performed along with patient's standard of care imaging session
Study: NCT00761566

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real preconditioning followed by Sham preconditioning
Description: Subjects in this arm of the study will first receive four 5 minute cycles of upper limb ischemia interspaced with 5 minutes of reperfusion by using a blood-pressure cuff inflated to a pressure of 15 mmHg greater than systolic arterial pressure. The subjects will then cross-over to the other arm of the study and receive four 5 minute cycles of upper limb ischemia interspaced with 5 minutes of reperfusion by using a sham procedure consisting of inflating the blood pressure cuff to 10 mmHg.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham preconditioning followed by Real preconditioning
Description: Subjects in this arm of the study will first receive four 5 minute cycles of upper limb ischemia interspaced with 5 minutes of reperfusion by using a sham procedure consisting of inflating the blood pressure cuff to 10 mmHg. They will then cross-over to the other arm of the study and receive four 5 minute cycles of upper limb ischemia interspaced with 5 minutes of reperfusion by using a blood-pressure cuff inflated to a pressure of 15 mmHg greater than systolic arterial pressure.
Study: NCT01248000

Intervention type: PROCEDURE
Intervention: FDG-PET
Description: PET interpretation is based on a site-to-site comparison of FDG uptake both before and after chemotherapy (qualitative approach), according to the criteria defined by Cheson (2008)
Study: NCT04543539

Intervention type: COMBINATION_PRODUCT
Intervention: IN.PACT™ AV Drug Coated Balloon (DCB) - Primary Cohort
Description: For the treatment of obstructive lesions up to 100 mm in length in the native arteriovenous dialysis fistulae with reference vessel diameters of 4 to 12 mm.

Intervention type: COMBINATION_PRODUCT
Intervention: IN.PACT™ AV Drug Coated Balloon (DCB) - Extended Cohort
Description: For treatment of stenosis in the AV circuit
Study: NCT03676452

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active@Home exergame training
Description: The Active@Home exergame is a multicomponent, motor-cognitive training for fall prevention in elderly adults. It mainly consists of three components; strength training, balance training and cognitive training. For strength training, Tai Chi-based movements are included. For balance training, dancing is included in the Active@Home exergame. Moreover, the Active@Home exergame explicitly targets specific attentional and executive functions. The Active@Home system set up is easy and consists of an HDMI dongle (to run the application) which must be plugged into the TV and four wearable sensors (to measure the movements).
Study: NCT04828655

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of a mobile application based on machine learning with the aim of improving health and body composition parameters.
Description: Specific diet program and moderate physical activity, all guided and mediated by a mobile application. As well as the recording and monitoring of periodic evaluations of health indicators.
Study: NCT03160924

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Recovery After Surgery (ERAS)
Description: same as above as described in the arms.
Study: NCT04173130

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anuscope with needles
Description: Injection of botulinum toxin into the anal sphincter with the investigational device (anuscope with needles).
Study: NCT04088461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin / Metformin Oral Tablet
Description: Linagliptin 2.5 mg + Metformin 850 mg twice daily plus a lifestyle modifications program
Study: NCT04511975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI188
Description: IBI188: 100 mg/mL, intravenous infusion once a week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine (VIDAZA) for Injection:100 mg per vial, subcutaneous injection will be administered for 7 days in each 28 day cycle
Study: NCT05043779

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Awake Airway Nasoendoscopy
Description: Preoperative Awake Airway Nasoendoscopy of upper airway